Does Retatrutide Affect Female Fertility? Reading the Signals That Exist

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• Retatrutide is investigational and not FDA-approved. FormBlends does not sell or supply it. This article is educational.
• Direct human fertility data for retatrutide has not been published. Phase 2 and Phase 3 trials excluded women who were pregnant or planning pregnancy.
• Animal reproductive toxicity signals exist across the GLP-1 receptor agonist class at maternally toxic doses.
• Most reported "fertility improvements" with GLP-1 drugs reflect weight loss restoring ovulation in women with obesity-related anovulation or PCOS, not direct ovarian effects.
• Approved GLP-1 medication labeling recommends discontinuation at least two months before planned pregnancy.

Direct answer

Direct retatrutide effects on female fertility have not been characterized in published human data. Phase 2 and Phase 3 trials enrolled non-pregnant women on reliable contraception. The closest available signals come from the GLP-1 class: animal reproductive toxicity at high doses, weight-loss-mediated improvements in ovulation in real-world use, and labeling cautions for approved drugs. The honest summary is that retatrutide-specific fertility data does not exist, and any clinical decision involves extrapolation.

Table of contents

1. What "fertility" means in this question
2. What the Phase 2 retatrutide trial recorded
3. The animal data and what it means
4. The class effect: GLP-1 agonists and reproductive outcomes
5. Weight-loss-mediated fertility improvement
6. PCOS, anovulation, and obesity-related infertility
7. What the approved-drug labels actually say
8. The contraception interaction question
9. Contrary view: skepticism about the class-effect extrapolation
10. Decision framework
11. FAQ
12. Sources

What "fertility" means in this question

"Fertility" is a composite of several biological processes: ovulation, ovarian reserve, oocyte quality, tubal patency, endometrial receptivity, and implantation success. A drug can affect one of these without affecting the others, and any patient asking the question may be focused on a different subset than the literature is measuring.

For weight-loss medications, the most commonly relevant subset is ovulation. Obesity is associated with anovulatory cycles through several mechanisms, including elevated peripheral estrogen, insulin resistance, and altered gonadotropin pulsatility. Weight loss often restores normal ovulation in this group. This is the fertility change patients most often observe with GLP-1 medications, and it is not a direct drug effect on the ovary.

What the Phase 2 retatrutide trial recorded

The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity. The eligibility criteria included reliable contraception for women of reproductive potential, standard practice for obesity-trial enrollment. Pregnant or breastfeeding women were excluded.

The published trial reported gastrointestinal adverse events, hepatic enzyme changes, heart rate effects, and skin events. Reproductive outcomes were not a pre-specified endpoint. There is no published count of pregnancies that occurred during the trial, no published menstrual cycle data, and no published fertility-marker information.

The TRIUMPH Phase 3 program is structured similarly. Reproductive outcomes are not the focus of the primary endpoints, which are weight loss, cardiometabolic markers, and safety.

The animal data and what it means

Preclinical reproductive toxicology is a standard requirement before human trials. For GLP-1 receptor agonists, the typical finding in rodent studies is that maternal exposure during organogenesis at doses producing maternal toxicity (weight loss, food intake reduction) is associated with reduced fetal weight and increased post-implantation loss. At lower exposures the effects diminish.

For tirzepatide specifically, the FDA labeling cites reproductive toxicology findings at exposures roughly equivalent to or below clinical maximum recommended human doses, depending on the species. The semaglutide labeling reports similar findings.

Eli Lilly has not published the full retatrutide preclinical reproductive toxicology package. Class-wide patterns suggest that similar findings are likely; this is the basis for the contraception requirement in trial enrollment.

The interpretation: animal studies are designed to detect risk signals, not to predict human outcomes precisely. The signal in rodents is a reason for caution in humans, not a verdict on human fertility.

The class effect: GLP-1 agonists and reproductive outcomes

Across the GLP-1 receptor agonist class, the labeled cautions for women of reproductive potential converge on a few points:

• Use is not recommended during pregnancy.
• Discontinuation is recommended approximately two months before planned conception, reflecting the long half-life of GLP-1 receptor agonists (semaglutide ~1 week, tirzepatide ~5 days, retatrutide ~6 days based on Phase 2 pharmacokinetics).
• Reliable contraception is recommended during use.
• Animal data support these cautions; human data are limited.

The two-month washout is a regulatory choice based on the long half-life and the time needed to clear the drug below detectable levels before a planned pregnancy. Five to six half-lives is the conventional clearance benchmark.

Weight-loss-mediated fertility improvement

The most observable "fertility effect" of GLP-1 medications in real-world use is weight-loss-mediated restoration of ovulation in women with obesity-related anovulation. Several mechanisms contribute:

• Improved insulin sensitivity. Insulin resistance contributes to hyperandrogenism and anovulation in PCOS. Weight loss improves insulin sensitivity, which can restore ovulation.
• Reduced peripheral estrogen. Adipose tissue converts androgens to estrogen via aromatase. Less adipose mass means less peripheral estrogen, allowing the hypothalamic-pituitary axis to function more normally.
• Restored gonadotropin pulsatility. Obesity-associated metabolic disturbance disrupts the GnRH pulse generator. Weight loss can restore normal pulsatility.

For women with PCOS, modest weight loss (5-10 percent of body weight) is associated with restored ovulation in many but not all cases. GLP-1 medications producing 15-20 percent or greater weight loss often produce substantial restoration of ovulation, which can result in unexpected pregnancies.

This effect is the source of online reports of "Ozempic babies." The mechanism is weight loss restoring fertility in a previously anovulatory state, not a direct fertility-enhancing effect of the drug.

PCOS, anovulation, and obesity-related infertility

PCOS affects approximately 6-12 percent of reproductive-age women and is the most common cause of anovulatory infertility. Obesity is highly prevalent in PCOS and amplifies the metabolic and reproductive phenotype.

Approved GLP-1 medications are not approved for PCOS treatment, but off-label use is common because of the substantial weight-loss benefit. Several small randomized trials have shown improvement in menstrual regularity, ovulation, and insulin sensitivity with semaglutide or liraglutide in women with PCOS.

Retatrutide has not been studied in PCOS specifically. The Phase 2 and Phase 3 trials enrolled general-population obesity, not PCOS subpopulations.

What the approved-drug labels actually say

For approved GLP-1 and dual-agonist medications:

Drug	Pregnancy category language	Pre-pregnancy discontinuation	Contraception advice
Semaglutide (Wegovy)	Use during pregnancy may cause fetal harm	2 months before planned pregnancy	Reliable contraception while taking
Semaglutide (Ozempic)	Use during pregnancy may cause fetal harm	2 months before planned pregnancy	Reliable contraception while taking
Tirzepatide (Zepbound)	Use during pregnancy may cause fetal harm; reduced oral contraceptive efficacy	1 month before planned pregnancy per labeling	Reliable contraception; non-oral or oral with backup during titration
Liraglutide (Saxenda)	Use during pregnancy may cause fetal harm	Discontinue if pregnant	Reliable contraception

None of these labels carry retatrutide-specific guidance because retatrutide has no FDA labeling. Clinicians and trial protocols apply class-effect reasoning.

The contraception interaction question

Tirzepatide labeling specifically notes that delayed gastric emptying can reduce absorption of oral contraceptives, particularly during dose escalation. The recommendation is to switch to a non-oral contraceptive or add a barrier backup method for four weeks after initiation and after each dose increase.

This interaction is biologically plausible for any GLP-1 receptor agonist because they all delay gastric emptying. Semaglutide labeling does not include the same explicit warning, but the mechanism overlaps. Retatrutide acts on GLP-1, GIP, and glucagon receptors. The gastric-emptying delay is similar in magnitude to tirzepatide based on Phase 2 pharmacology.

The practical implication is that women using oral contraceptives during retatrutide trial participation may have reduced contraceptive efficacy, which is part of why trials require multiple contraceptive methods or non-oral methods.

Contrary view: skepticism about the class-effect extrapolation

Some clinicians argue that extrapolating animal fertility signals to humans overstates the actual risk, particularly when the animal effects occur only at maternally toxic doses.

The argument has several components. First, the doses producing fetal effects in rodent studies are well above typical clinical doses on a body-weight or AUC basis. Second, the post-marketing surveillance for approved GLP-1 medications has not detected a clear teratogenic signal in human pregnancies that occurred during use, though the data are limited. Third, the weight-loss-mediated improvement in pregnancy outcomes in women with severe obesity is well documented and may offset some theoretical risk.

The counterargument: absence of evidence in limited post-marketing data is not evidence of absence. The conservative position (discontinuation before planned pregnancy) reflects a precautionary stance appropriate for a relatively new drug class without long-term reproductive outcome data.

For retatrutide specifically, the precautionary stance is more defensible because the drug is investigational and the human safety database is smaller than for approved drugs.

Decision framework

If you are actively trying to conceive:

• Retatrutide is not available outside trials. Trial enrollment is incompatible with planned conception.
• For approved GLP-1 drugs, labeling recommends discontinuation two months before conception attempts.

If you have PCOS or obesity-related anovulation:

• Weight loss through any method often restores ovulation. Approved obesity medications are an established option.
• A reproductive endocrinologist can advise on timing of medication and conception.

If you are postpartum or breastfeeding:

• GLP-1 drugs are not recommended during breastfeeding because excretion into breast milk and infant effects are not well characterized.

If you are a trial participant:

• Trial protocols include specific contraception requirements. Pregnancy during participation is a protocol deviation and requires immediate discontinuation and follow-up.

FAQ

Does retatrutide affect female fertility? No retatrutide-specific human fertility data has been published. Class-effect reasoning from approved GLP-1 drugs applies.

What do animal studies say? Class-wide animal data show reproductive toxicity signals at maternally toxic doses. Retatrutide-specific preclinical reproductive data has not been fully published.

Can GLP-1 drugs improve fertility? Indirectly, through weight-loss-mediated restoration of ovulation in obesity-related anovulation. Not through direct fertility-enhancing effects.

Should women trying to conceive use retatrutide? Retatrutide is investigational; trial enrollment excludes planned conception. For approved GLP-1 medications, labeling recommends discontinuation two months before conception.

Does retatrutide affect menstrual cycles? Menstrual changes are reported with approved GLP-1 drugs and are mostly attributed to weight loss. Retatrutide-specific data is not published.

Does it interfere with birth control? The gastric-emptying delay can reduce oral contraceptive absorption, particularly during dose escalation. Tirzepatide labeling addresses this explicitly.

What about long-term fertility? Long-term reproductive outcome data for any GLP-1 medication is limited.

Is retatrutide FDA-approved? No. Retatrutide is investigational and not FDA-approved.

What should I ask a clinician? Timing of discontinuation before planned pregnancy, contraceptive choice during use, and the balance of weight-loss benefit against absence of safety data.

Related guides

• Retatrutide for Women: What Female Patients Should Know
• Does Retatrutide Affect Testosterone or Libido? What the Class Data Suggests
• Does Retatrutide Affect Libido? What the Data Show and What They Miss
• Retatrutide and Male Fertility: A Closer Look at What the Evidence Actually Shows
• Retatrutide and Fertility Impact
• Retatrutide for Pcos Fertility Improvement

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). NEJM. 2023;389:514-526.
2. Rosenstock J et al. Retatrutide in Type 2 Diabetes. The Lancet. 2023;402:529-544.
3. Wegovy (semaglutide) prescribing information. Novo Nordisk. Revised 2024.
4. Zepbound (tirzepatide) prescribing information. Eli Lilly. Revised 2024.
5. Saxenda (liraglutide) prescribing information. Novo Nordisk. Revised 2023.
6. Jensterle M et al. Semaglutide in women with PCOS: pilot randomized trial. European Journal of Endocrinology. 2022;186:535-545.
7. ACOG Practice Bulletin. Polycystic Ovary Syndrome. Obstetrics & Gynecology. 2018;131:e157-e171.
8. Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction. 2010;140:347-364.
9. Norman RJ et al. Improving reproductive performance in overweight/obese women with effective weight management. Human Reproduction Update. 2004;10:267-280.
10. Endocrine Society Clinical Practice Guideline. PCOS Management. 2023.
11. ClinicalTrials.gov. TRIUMPH Program Records. Accessed May 2026.
12. FDA. Drug Development for Pregnant Women: Considerations for Inclusion in Clinical Trials. Guidance. 2022.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384:989-1002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients to independent licensed clinicians and to U.S.-licensed pharmacies. FormBlends does not manufacture, prescribe, or dispense medication.

Compounded Medication Notice. Compounded preparations are produced by 503A pharmacies for individual patients and have not been reviewed by the FDA. They are not interchangeable with branded approved products. Retatrutide is not lawfully compoundable because it is investigational.

Results Disclaimer. Reproductive and fertility outcomes vary widely by individual. Statements about ovulation restoration with weight loss describe general patterns in published literature, not individual predictions.

Trademark Notice. Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda are registered trademarks of Novo Nordisk and Eli Lilly. Retatrutide is an investigational compound from Lilly. FormBlends has no affiliation with these companies.